Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
Healthcare
$2.11 +1.84%
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
52W Low $2.40High $5.45
Volume 2.49M
Average 3.15M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$228.52M
FY 2025 · Annual
Net Income
-$223.12M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.03M |
| Gross Profit | 0 | 0 | 0 | 0 | (11.03M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 125.48M | 165.57M | 186.34M | 171.24M | 142.02M |
| Selling, General & Admin | 41.77M | 58.77M | 73.32M | 101.96M | 86.5M |
| Operating Expenses | 167.25M | 224.34M | 259.66M | 273.21M | 217.49M |
| Depreciation & Amortization | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| EBITDA | (157.81M) | (213.69M) | (236.62M) | (247.49M) | (210.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (167.25M) | (224.34M) | (259.66M) | (273.21M) | (228.52M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3.07M | 3.89M | 15.94M | 18.22M | 10.62M |
| Interest Expense | 5.89M | 1.91M | 1.88M | 1.89M | 1.89M |
| Other Income / Expenses | (1.82M) | 2.48M | 14.06M | 14.46M | 5.39M |
| Income Before Tax | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| EPS (Diluted) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| 63.24M | 68.15M | 84.01M | 94.81M | 111.12M | |
| 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
RCKT Earnings Waterfall · TTM
NASDAQ:RCKT · Revenue to Net Income
Key Ratios
EPS$-1.87
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$209.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.87, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 30, 2026 |
How much revenue does RCKT generate?
Rocket Pharmaceuticals, Inc. (RCKT) reported $0.00 of revenue in fiscal 2025.
Is RCKT profitable?
Rocket Pharmaceuticals, Inc. (RCKT) reported -$223.12M of net income.
Continue the stock analysis
Jump to another research area for this company.